Correlation Between Cadrenal Therapeutics, and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Lineage Cell Therapeutics, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Lineage Cell.

Diversification Opportunities for Cadrenal Therapeutics, and Lineage Cell

0.54

Correlation Coefficient

Cadrenal Therapeutics,  Lineage Cell

Very weak diversification

The 3 months correlation between Cadrenal and Lineage is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Lineage Cell go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Lineage Cell

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 0.84 times more return on investment than Lineage Cell. However, Cadrenal Therapeutics, Common is 1.18 times less risky than Lineage Cell. It trades about 0.12 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  1,423  in Cadrenal Therapeutics, Common on December 30, 2024 and sell it today you would earn a total of  423.00  from holding Cadrenal Therapeutics, Common or generate 29.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Lineage Cell Therapeutics

Cadrenal Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Lineage Cell Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Lineage Cell may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Cadrenal Therapeutics, and Lineage Cell

The main advantage of trading using opposite Cadrenal Therapeutics, and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind Cadrenal Therapeutics, Common and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.